Description
Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. Its product pipeline includes clinical product candidates: BPX-501, which is an adjunct T-cell therapy administered after allogeneic hematopoietic stem cell transplantation; BPX-201, which is a dendritic cell cancer vaccine; and Preclinical product candidates: BPX-701, which is a T cell receptor (TCR) product candidate for solid tumors; BPX-401, which is a CAR-T product candidate for hematological cancers that express the CD19 antigen, and BPX-601, which is a TCR product candidate for solid tumors expressing the preferentially-expressed antigen in melanoma (PRAME). Its Chemical Induction of Dimerization (CID) technology platform, engineers and controls components of the immune system in real time.
Address
2130 W Holcombe Blvd Ste 850
HOUSTON, TX 77030-3308
United States
HOUSTON, TX 77030-3308
United States
Website
http://www.bellicum.comKey stats and ratios
| Q3 (Sep '14) | 2013 | |
| Net profit margin | -620.69% | -410.62% |
| Operating margin | -439.02% | -408.21% |
| EBITD margin | - | -377.95% |
| Return on average assets | -39.70% | -79.18% |
| Return on average equity | - | - |
| Employees | 30 |
No comments:
Post a Comment